Evidence map›Paper›PMID 34008255›Full record

ArticleJournal of peptide science : an official publication of the European Peptide Society2021

Ergothioneine in a peptide: Substitution of histidine with 2-thiohistidine in bioactive peptides.

Kaelyn A Jenny, Erik L Ruggles, Matthew D Liptak, Douglas S Masterson, Robert J Hondal

Open access · greenAbstract read
In one paragraph

Article in Journal of peptide science : an official publication of the European Peptide Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. An Effective Method for Isolating Ergothioneine Analogues for Use in Peptide Synthesis: 2-Thiohistidine and Fmoc-2-Thiohistidine.Journal of peptide science : an official publication of the European Peptide Society · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kaelyn A JennyDepartment of Biochemistry, College of Medicine, University of Vermont, Burlington, Vermont, USA.
Erik L RugglesDepartment of Biochemistry, College of Medicine, University of Vermont, Burlington, Vermont, USA.
Matthew D LiptakDepartment of Chemistry, University of Vermont, Burlington, Vermont, USA.
Douglas S MastersonSchool of Mathematics and Natural Sciences, Chemistry and Biochemistry, University of Southern Mississippi, Hattiesburg, Mississippi, USA.
Robert J HondalDepartment of Biochemistry, College of Medicine, University of Vermont, Burlington, Vermont, USA.ORCID https://orcid.org/0000-0002-1466-2852
University of Vermont · USUniversity of Southern Mississippi · US

Funding

Selenocyanate as a novel treatment of cystic fibrosis lung diseaseR01HL141146 · NHLBI · NATIONAL JEWISH HEALTH · PI DAY, BRIAN J, HONDAL, ROBERT J · 2019 to 2022
$1.6M
NHLBI NIH HHS HL141146NHLBI NIH HHS R01 HL141146
6 · The paper itself

Abstract

Ergothioneine (EGT) is the betaine of 2-thiohistidine (2-thioHis) and may be the last undiscovered vitamin. EGT cannot be incorporated into a peptide because the α-nitrogen is trimethylated, although this would be advantageous as an EGT-like moiety in a peptide would impart unique antioxidant and metal chelation properties. The amino acid 2-thioHis is an analogue of EGT and can be incorporated into a peptide, although there is only one reported occurrence of this in the literature. A likely reason is the harsh conditions reported for protection of the thione, with similarly harsh conditions used in order to achieve deprotection after synthesis. Here, we report a novel strategy for the incorporation of 2-thioHis into peptides in which we decided to leave the thione unprotected. This decision was based upon the reported low reactivity of EGT with 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB), a very electrophilic disulfide. This strategy was successful, and we report here the synthesis of 2-thioHis analogues of carnosine (βAH), GHK-tripeptide, and HGPLGPL. Each of these peptides contain a histidine (His) residue and possesses biological activity. Our results show that substitution of His with 2-thioHis imparts strong antioxidant, radical scavenging, and copper binding properties to the peptide. Notably, we found that the 2-thioHis analogue of GHK-tripeptide was able to completely quench the hydroxyl and ABTS radicals in our assays, and its antioxidant capacity was significantly greater than would be expected based on the antioxidant capacity of free 2-thioHis. Our work makes possible greater future use of 2-thioHis in peptides.

Indexed as

ErgothioneineAntioxidantsHistidinePeptidesAntioxidantsErgothioneineHistidinePeptides2-thioantioxidantantioxidant peptidecarnosinecopper bindingergothioneineGHK-tripeptidehistidine

Identifiers

PMID34008255
PMCPMC8443123
OpenAlexW3161628744

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.